Development of BTK inhibitors for the treatment of B-cell malignancies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of BTK inhibitors for the treatment of B-cell malignancies
Authors
Keywords
BTK, B-cell malignancies, Ibrutinib, BTK inhibitors, Noncovalent BTK inhibitors
Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 42, Issue 2, Pages 171-181
Publisher
Springer Nature
Online
2019-01-31
DOI
10.1007/s12272-019-01124-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
- (2018) Constantine S Tam et al. Future Oncology
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
- (2018) Maddalena Mazzucchelli et al. Mediterranean Journal of Hematology and Infectious Diseases
- LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
- (2018) Barbara Brandhuber et al. Clinical Lymphoma Myeloma & Leukemia
- Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
- (2017) T. Seiler et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
- (2017) J. Trotman et al. HEMATOLOGICAL ONCOLOGY
- Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2017) Georg Lenz JOURNAL OF CLINICAL ONCOLOGY
- Targeting of B-cell receptor signalling in B-cell malignancies
- (2017) M. Jerkeman et al. JOURNAL OF INTERNAL MEDICINE
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Btk inhibition treats TLR7/IFN driven murine lupus
- (2016) Andrew T. Bender et al. CLINICAL IMMUNOLOGY
- Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
- (2016) Prithviraj Bose et al. Expert Opinion on Drug Metabolism & Toxicology
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- From identification of the BTK kinase to effective management of leukemia
- (2016) C I E Smith ONCOGENE
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
- (2015) Urte Gayko et al. Annals of the New York Academy of Sciences
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
- (2015) Na Li et al. CANCER RESEARCH
- Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
- (2015) M. Skarzynski et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma
- (2014) M. J. Vogel et al. BLOOD
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
- (2014) Chung-Shien Lee et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
- (2013) Amin Aalipour et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Using the Biology of Chronic Lymphocytic Leukemia to Choose Treatment
- (2011) P. Hillmen Hematology-American Society of Hematology Education Program
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started